The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda… - Cancer discovery, 2020 - AACR
Despite decades of research, efforts to directly target KRAS have been challenging.
MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that …
MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that …
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized by KRAS-and autophagy-
dependent tumorigenic growth, but the role of KRAS in supporting autophagy has not been …
dependent tumorigenic growth, but the role of KRAS in supporting autophagy has not been …
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
GA Hobbs, NM Baker, AM Miermont, RD Thurman… - Cancer discovery, 2020 - AACR
Allele-specific signaling by different KRAS alleles remains poorly understood. The KRAS
G12R mutation displays uneven prevalence among cancers that harbor the highest …
G12R mutation displays uneven prevalence among cancers that harbor the highest …
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
DM Briere, S Li, A Calinisan, N Sudhakar… - Molecular cancer …, 2021 - AACR
Abstract KRASG12C inhibitors, including MRTX849, are promising treatment options for
KRAS-mutant non–small cell lung cancer (NSCLC). PD-1 inhibitors are approved in NSCLC; …
KRAS-mutant non–small cell lung cancer (NSCLC). PD-1 inhibitors are approved in NSCLC; …
Functional and biological heterogeneity of KRASQ61 mutations
Missense mutations at the three hotspots in the guanosine triphosphatase (GTPase) RAS—
Gly12, Gly13, and Gln61 (commonly known as G12, G13, and Q61, respectively)—occur …
Gly12, Gly13, and Gln61 (commonly known as G12, G13, and Q61, respectively)—occur …
[HTML][HTML] Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers
We address whether combinations with a pan-RAF inhibitor (RAFi) would be effective in
KRAS mutant pancreatic ductal adenocarcinoma (PDAC). Chemical library and CRISPR …
KRAS mutant pancreatic ductal adenocarcinoma (PDAC). Chemical library and CRISPR …
RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling
Cancer-associated mutations in the guanosine triphosphatase (GTPase) RHOA are found at
different locations from the mutational hotspots in the structurally and biochemically related …
different locations from the mutational hotspots in the structurally and biochemically related …
Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN
Background Colorectal cancer (CRC) represents the fourth leading cause of cancer-related
deaths. The heterogeneity of CRC identity limits the usage of cell lines to study this type of …
deaths. The heterogeneity of CRC identity limits the usage of cell lines to study this type of …
Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens
AL Hunt, NW Bateman, W Barakat, S Makohon-Moore… - Iscience, 2021 - cell.com
Enriched tumor epithelium, tumor-associated stroma, and whole tissue were collected by
laser microdissection from thin sections across spatially separated levels of ten high-grade …
laser microdissection from thin sections across spatially separated levels of ten high-grade …
Mapping three-dimensional intratumor proteomic heterogeneity in uterine serous carcinoma by multiregion microsampling
AL Hunt, NW Bateman, W Barakat… - Clinical proteomics, 2024 - Springer
Background Although uterine serous carcinoma (USC) represents a small proportion of all
uterine cancer cases, patients with this aggressive subtype typically have high rates of …
uterine cancer cases, patients with this aggressive subtype typically have high rates of …